At NeoGenomics, we’re thrilled to announce the launch of our brand-new National Mobile Phlebotomy Service for our blood-based tests. This service addresses the challenges and impact of COVID-19 for oncology patients needing timely testing to make sure effective medical diagnosis and disease development monitoring.
Tests provided include InVisionFirst ®-Lung, advanced non-small cell lung cancer liquid biopsy test, and the NeoLAB ® liquid biopsy suite of tests encompassing strong growth and hematologic cancers.
Listen to Douglas VanOort, NeoGenomics’ Chairman and Chief Executive Officer, as he describes the effect of COVID-19 on cancer clients across the US; and why it is so important that this in-home service addresses client worries of exposure to COVID-19 to make sure the efficient continuity of care so crucial in the treatment and tracking of cancer clients.
NeoGenomics will use in-home mobile phlebotomy services through 2 phlebotomy business for broad nationwide geographic coverage to ensure tests are carried out easily and rapidly for fast outcomes. NeoGenomics will schedule the blood sample collection at the patient’s desired place and cover the expense of the mobile phlebotomy blood service.
For additional information about NeoGenomics’ National Mobile Phlebotomy Service, please contact NeoGenomics’ Client Services at 1-866-776-5907.
The post Releasing NeoGenomics’ New National Mobile Phlebotomy Service for Blood-Based Oncology Tests appeared first on Phlebotomy Technician Program.
from https://bit.ly/2GWlJZi
No comments:
Post a Comment